Page 39 - Read Online

Laubach et al. Cancer Drug Resist 2023;6:611-41 https://dx.doi.org/10.20517/cdr.2023.60 Page 641

252. Wang Z, Aguilar EG, Luna JI, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint
blockade. Nat Med 2019;25:141-51. DOI PubMed PMC
253. Manzo T, Prentice BM, Anderson KG, et al. Accumulation of long-chain fatty acids in the tumor microenvironment drives
+
dysfunction in intrapancreatic CD8 T cells. J Exp Med 2020;217:e20191920. DOI PubMed PMC
254. Huang SC, Everts B, Ivanova Y, et al. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nat
Immunol 2014;15:846-55. DOI PubMed PMC
255. Wang H, Franco F, Tsui YC, et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors.
Nat Immunol 2020;21:298-308. DOI PubMed PMC
256. Yan D, Adeshakin AO, Xu M, et al. Lipid metabolic pathways confer the immunosuppressive function of myeloid-derived suppressor
cells in tumor. Front Immunol 2019;10:1399. DOI PubMed PMC
257. Hossain F, Al-Khami AA, Wyczechowska D, et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of
myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol Res 2015;3:1236-47. DOI PubMed PMC
258. Auciello FR, Bulusu V, Oon C, et al. A stromal lysolipid-autotaxin signaling axis promotes pancreatic tumor progression. Cancer
Discov 2019;9:617-27. DOI PubMed PMC
259. Federico L, Jeong KJ, Vellano CP, Mills GB. Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer
progression. J Lipid Res 2016;57:25-35. DOI PubMed PMC
260. Matas-Rico E, Frijlink E, van der Haar Àvila I, et al. Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor
+
infiltration of CD8 T cells. Cell Rep 2021;37:110013. DOI PubMed PMC
261. Mathew D, Kremer KN, Strauch P, Tigyi G, Pelanda R, Torres RM. LPA is an inhibitory receptor that suppresses CD8 T-cell
5
cytotoxic function via disruption of early TCR signaling. Front Immunol 2019;10:1159. DOI PubMed PMC
262. Oda SK, Strauch P, Fujiwara Y, et al. Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression. Cancer
Immunol Res 2013;1:245-55. DOI PubMed PMC
263. Kremer KN, Buser A, Thumkeo D, et al. LPA suppresses T cell function by altering the cytoskeleton and disrupting immune synapse
formation. Proc Natl Acad Sci U S A 2022;119:e2118816119. DOI PubMed PMC
264. Turner JA, Fredrickson MA, D’Antonio M, et al. Lysophosphatidic acid modulates CD8 T cell immunosurveillance and metabolism
to impair anti-tumor immunity. Nat Commun 2023;14:3214. DOI PubMed PMC
265. Deken M, Niewola K, Matas-rico E, et al. 922 A novel autotaxin inhibitor, IOA-289, modulates tumor, immune and stromal cell
function and has monotherapy activity in fibrotic cancer models. J Immunother Cancer 2021;9:A967. DOI
266. Deken MA, Niewola-Staszkowska K, Peyruchaud O, et al. Characterization and translational development of IOA-289, a novel
autotaxin inhibitor for the treatment of solid tumors. Immunooncol Technol 2023;18:100384. DOI PubMed PMC
267. Xiong Q, Feng D, Wang Z, et al. Fatty acid synthase is the key regulator of fatty acid metabolism and is related to immunotherapy in
bladder cancer. Front Immunol 2022;13:836939. DOI PubMed PMC
268. Wang Q, Tian N, Zhang W, et al. Fatty acid synthase mutations predict favorable immune checkpoint inhibitor outcome and response
in melanoma and non-small cell lung cancer patients. Cancers 2022;14:5638. DOI PubMed PMC
269. Murphy WJ, Longo DL. The surprisingly positive association between obesity and cancer immunotherapy efficacy. JAMA
2019;321:1247-8. DOI PubMed
270. Woodall MJ, Neumann S, Campbell K, Pattison ST, Young SL. The effects of obesity on anti-cancer immunity and cancer
immunotherapy. Cancers 2020;12:1230. DOI PubMed PMC
271. McQuade JL, Daniel CR, Hess KR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated
with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol 2018;19:310-22. DOI
PubMed PMC
272. Cortellini A, Bersanelli M, Buti S, et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1
immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer 2019;7:57. DOI PubMed PMC
273. Diana A, Wang LM, D'Costa Z, et al. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the
desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget 2016;7:40992-1004. DOI PubMed PMC
274. Shen T, Zhou L, Shen H, et al. Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic
cancer. Sci Rep 2017;7:7848. DOI PubMed PMC
275. Winograd R, Byrne KT, Evans RA, et al. Induction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4
blockade and improves survival in pancreatic carcinoma. Cancer Immunol Res 2015;3:399-411. DOI PubMed PMC